Revance Wins Again Over Investors’ Claims of Wrinkle Drug Fraud

Revance Therapeutics Inc. has prevailed again over investors’ claims that the biotech company misled them about the timeline for regulatory approval of the anti-wrinkle injection Daxi.

The investors failed to show that Revance’s executives had an intent to deceive, manipulate, or defraud, Judge Araceli Martínez-Olguín in the US District Court for the Northern District of California said in a Jan. 17 order dismissing a second amended complaint without leave to amend. She had dismissed the previous complaint in a March 30 decision.

Even if the investors “could show that Revance executives had knowledge of issues with the approval process, ...